Dementia – Epidemiology – Middle East & Africa
Clarivate Epidemiology’s coverage of dementia comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of dementia for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets of the United States, Europe, and Japan and 10 years for the other countries covered in this report.
DRG Epidemiology’s dementia forecast will answer the following questions:
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of dementia over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
In total, Clarivate Epidemiology forecasts four dementia patient populations, as follows:
- Total prevalent cases of dementia.
- Total prevalent cases of mild dementia.
- Total prevalent cases of moderate dementia.
- Total prevalent cases of severe dementia.
Note: Coverage may vary by country.
Table of contents
- Dementia - Epidemiology - Middle East & Africa
- Introduction
- Key Findings
- Total Prevalence of Dementia per 1,000 People Aged 65+ in 2020 and 2030
- Total Prevalence of Dementia per 1,000 People Aged 65+ in 2020 and 2030
- Relative Sizes of the Contributing Factors to the Trend in Total Prevalent Cases of Dementia over the Next 10 Years
- Relative Sizes of the Contributing Factors to the Trend in Total Prevalent Cases of Dementia over the Next 10 Years
- Total Prevalent Cases of Dementia by Severity
- Total Prevalent Cases of Dementia by Severity
- Key Findings
- Epidemiology Data
- Methods
- Reference Materials
- Introduction
Oliver Blandy, M.Sc., is a senior epidemiologist at Clarivate. Previously, Oliver worked as a research assistant for Imperial College London, where he was the lead for several studies within an NIRH-funded research group investigating healthcare-associated infections and antimicrobial resistance. He holds an M.Sc. from the University of Bristol, where he specialized in nutrition, physical activity, and public health. He also holds a B.Sc. in chemistry and a postgraduate certificate in education, both from the University of Bristol.
Nishant Kumar, M.P.H., is a senior director on the Epidemiology team at Clarivate. His areas of expertise are oncology and CNS diseases, including Alzheimer’s disease and dementia. His key interests in oncology are modeling disease progression and drug-treatable incident and prevalent populations. Previously, Mr. Kumar sized patient populations for rare and niche diseases, such as graft-versus-host disease and Duchenne muscular dystrophy. He earned his M.P.H. with a concentration in epidemiology and statistics from King’s College in London and a B.Sc. (Honors) in medical studies from the University of Birmingham.